Logomix
Harumi
About Logomix
Logomix is a pioneering synthetic biology company. With its unprecedented genome engineering platform, Geno-Writing™, Logomix facilitates precise and Mb-scale manipulation of genomic sequences within human cells, leads the development of super-functionalized hypoimmune cells to address critical limitations in contemporary cell therapy approaches, and unlocks the potential with a TAM of solid tumors and 70,000 genetic diseases worth trillion of dollars.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $22.7M
- Last round: Series Unknown (Jul 2025)
- Website: logomix.bio
- Phone: [email protected]
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/logomix-47169 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.